GlassScriptPhysician profile
Hyman Kaplan
NPI 1356310932
$1,177.23
in general payments reported to CMS, 2019-2025
20 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $30.86 · 2021: $199 · 2022: $230 · 2023: $131 · 2024: $14.99 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $278.63 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $222.44 | 2019-2024 | Tezspire |
| Csl Behring | $170.81 | 2019-2025 | Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $62.98 | 2021-2023 | Takhzyro |
| Incyte Corporation | $50.06 | 2023-2025 | Opzelura |
| Genentech USA, INC. | $46.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $41.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.94 | 2025 | |
| Alk-Abello, INC | $38.83 | 2020-2021 | |
| Abbvie INC. | $32.89 | 2023 | |
| Glaxosmithkline, LLC. | $31.96 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.22 | 2022 | |
| Amgen INC. | $24.53 | 2022 | |
| Blueprint Medicines Corporation | $21.37 | 2023 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $15.36 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $15.00 | 2022 | |
| Ionis Pharmaceuticals, INC. | $14.96 | 2025 | |
| Pfizer INC. | $14.67 | 2019 | |
| Genzyme Corporation | $14.39 | 2021 | |
| Kaleo, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyman Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.